Adverse events ‐ serious · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
Urtoxazumab (3.0 mg/kg) may leads to lower adverse events ‐ serious compared with placebo (low certainty).
1 finding from 1 review
Adverse events ‐ serious · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
1 finding from 1 review
Serious adverse events ( · adults with sickle cell disease in a vaso‐occlusive crisis
1 finding from 1 review
Adverse events (serious) · carpal tunnel syndrome
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Serious adverse events ( · children with either displaced distal radius fracture with intact or displaced ulna fracture (both‐bone fracture), or minimally displaced…
1 finding from 1 review
SAEs · NSTI
Intravenous immunoglobulin showed no clear difference in serious adverse events (SAE) compared with placebo (low certainty).
1 finding from 1 review
SAEs · NSTI
It is very uncertain whether moxifloxacin changes serious adverse events (SAE) compared with amoxicillin‐clavulanate (very low certainty).
1 finding from 1 review
SAEs · NSTI
It is very uncertain whether AB103 changes serious adverse events (SAE) compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events (during · children or adults with Types I or II HAE
Berotralstat showed no clear difference in serious adverse events (during compared with placebo or active control (low certainty).
1 finding from 1 review
Serious adverse events (during · children or adults with Types I or II HAE
It is very uncertain whether C1 esterase inhibitor changes serious adverse events (during compared with placebo or active control (very low certainty).
1 finding from 1 review
Serious adverse events (during · children or adults with Types I or II HAE
It is very uncertain whether plasma‐derived C1 esterase inhibitor changes serious adverse events (during compared with placebo or active control (very low certainty).
1 finding from 1 review
Serious adverse events (during · children or adults with Types I or II HAE
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (during · children or adults with Types I or II HAE
It is very uncertain whether recombinant human C1 esterase inhibitor changes serious adverse events (during compared with placebo or active control (very low certainty).
1 finding from 1 review
Serious adverse events (during · children or adults with Types I or II HAE
It is very uncertain whether avoralstat changes serious adverse events (during compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events (during · children or adults with Types I or II HAE
Lanadelumab showed no clear difference in serious adverse events (during compared with placebo or active control (low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events (number) · people with acute pancreatitis
1 finding from 1 review
Serious adverse events (number) · participants with alcoholic hepatitis (all severity)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (number) · participants with alcoholic hepatitis (all severity)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (number) · participants with alcoholic hepatitis (all severity)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (number) · participants with severe alcoholic hepatitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found